Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/30/16
End: 05/31/25
Due: 05/31/26
Phase: N/A
Priority: Normal
Start: 06/01/18
End: 03/07/22
Due: 03/07/23
Phase: N/A
Priority: Normal
Start: 04/04/17
End: 06/04/22
Due: 06/04/23
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates | NCT02723331 | Academic Thoracic Oncology Medical Investigators Consortium | user2@example.com | None | 2016-12-30 | 2025-05-31 | 2026-05-31 | - | - | 2025-07-14 |
| Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer | NCT03542877 | Academic Thoracic Oncology Medical Investigators Consortium | user2@example.com | None | 2018-06-01 | 2022-03-07 | 2023-03-07 | - | - | 2025-07-14 |
| A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients | NCT02879617 | Academic Thoracic Oncology Medical Investigators Consortium | user2@example.com | None | 2017-04-04 | 2022-06-04 | 2023-06-04 | - | - | 2025-07-14 |